NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The main purposes of Phase 1b of this study are to determine the following in participants
with advanced solid tumors:
- Safety and tolerability of NT-I7 in combination with pembrolizumab
- Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D)
The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity
of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI)
treated and naïve relapsed and refractory (R/R) tumors.
The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor
infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R
ovarian cancer (OC).